Immunotech Biopharm Ltd (6978.HK)
HKD 4.1
(3.8%)
HKD 4.1
(3.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -334.81 Million CNY | 5.11% |
| 2022 | -352.83 Million CNY | 6.03% |
| 2021 | -375.48 Million CNY | 18.08% |
| 2020 | -458.34 Million CNY | -325.53% |
| 2019 | -107.71 Million CNY | -209.82% |
| 2018 | -34.76 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -46.25 Thousand CNY | 57.31% |
| 2024 Q2 | -46.25 Thousand CNY | 0.0% |
| 2023 Q1 | -59.05 Thousand CNY | 33.56% |
| 2023 Q2 | -59.05 Thousand CNY | 0.0% |
| 2023 Q3 | -108.35 Thousand CNY | -83.47% |
| 2023 FY | -334.81 Million CNY | 5.11% |
| 2023 Q4 | -108.35 Thousand CNY | 0.0% |
| 2022 Q2 | -70.16 Thousand CNY | 0.0% |
| 2022 Q4 | -88.89 Thousand CNY | 0.0% |
| 2022 Q3 | -88.89 Thousand CNY | -26.69% |
| 2022 Q1 | -70.16 Thousand CNY | 32.19% |
| 2022 FY | -352.83 Million CNY | 6.03% |
| 2021 Q2 | -73.64 Thousand CNY | 0.0% |
| 2021 FY | -375.48 Million CNY | 18.08% |
| 2021 Q4 | -103.46 Thousand CNY | 0.0% |
| 2021 Q3 | -103.46 Thousand CNY | -40.48% |
| 2021 Q1 | -73.64 Thousand CNY | 44.42% |
| 2020 FY | -458.34 Million CNY | -325.53% |
| 2020 Q4 | -132.51 Thousand CNY | 0.0% |
| 2020 Q3 | -132.51 Thousand CNY | -52.3% |
| 2020 Q2 | -87 Thousand CNY | 0.0% |
| 2020 Q1 | -87 Thousand CNY | -198.2% |
| 2019 Q2 | -25.22 Thousand CNY | 0.0% |
| 2019 Q1 | -25.22 Thousand CNY | 0.0% |
| 2019 Q4 | -29.17 Thousand CNY | 0.0% |
| 2019 FY | -107.71 Million CNY | -209.82% |
| 2019 Q3 | -29.17 Thousand CNY | -15.68% |
| 2018 FY | -34.76 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 572.401% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 2040.98% |